Patient characteristics
| . | PTCy+Aba (n = 25) . | SOC (n = 15) . |
|---|---|---|
| Sex | ||
| Male | 14 | 11 |
| Female | 11 | 4 |
| Age (mean), y | 48 (±15.5) | 47 (±16.5) |
| Disease | ||
| ALL | 7 | 5 |
| AML | 9 | 7 |
| BP-CML | 1 | 0 |
| MDS/MPN | 1 | 1 |
| MDS | 4 | 0 |
| MF | 3 | 1 |
| Lymphoma | 0 | 1 |
| Disease status | ||
| CR1 | 9 | 12 |
| CR2 | 8 | 2 |
| SD | 8 | 1 |
| Conditioning | ||
| TBI/Cy | 6 | 4 |
| Flu/Bu4 | 13 | 6 |
| Flu/Mel | 6 | 5 |
| Donor | ||
| MRD | 8 | 6 |
| MUD | 17 | 9 |
| . | PTCy+Aba (n = 25) . | SOC (n = 15) . |
|---|---|---|
| Sex | ||
| Male | 14 | 11 |
| Female | 11 | 4 |
| Age (mean), y | 48 (±15.5) | 47 (±16.5) |
| Disease | ||
| ALL | 7 | 5 |
| AML | 9 | 7 |
| BP-CML | 1 | 0 |
| MDS/MPN | 1 | 1 |
| MDS | 4 | 0 |
| MF | 3 | 1 |
| Lymphoma | 0 | 1 |
| Disease status | ||
| CR1 | 9 | 12 |
| CR2 | 8 | 2 |
| SD | 8 | 1 |
| Conditioning | ||
| TBI/Cy | 6 | 4 |
| Flu/Bu4 | 13 | 6 |
| Flu/Mel | 6 | 5 |
| Donor | ||
| MRD | 8 | 6 |
| MUD | 17 | 9 |
BP-CML, blast phase chronic myelogenous leukemia; Bu4, busulfan at a myeloablative dose; CR1/2, complete remission 1/2; Flu, fludarabine; MDS, myelodysplastic syndrome; Mel, melphalan; MF, myelofibrosis; MPN, myeloproliferative neoplasm; MRD, matched related donor; MUD, matched unrelated donor; SD, stable disease; TBI, total body irradiation.